Company intelligence / Profile preview

Angimmune LLC

Rockville, Maryland, United Statesangimmune.com ↗

Ownership: Private
Employees: ~30
Development stage: Phase 2

Overview

Angimmune has conducted a Phase 2 multi-center randomized clinical trial evaluating the effectiveness of a single four-day treatment with Resimmune compared to oral Zolinza in patients with stage IB/IIB mycosis fungoides. Their divalent Anti-CD3 biologic has shown 2+ year anti-tumor effects in CTCL after a single cycle.

Therapeutic areas: OncologyImmunologyHematology
Modalities: ImmunotoxinsFusion proteinAnti-T cell immunotoxinBiologic
Industry: Biotech

Drug pipeline

1 asset

A-dmDT390-bisFv(UCHT1)

Partnerships

Scott & White Healthcare

Beyond the preview

Go deeper on Angimmune LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Angimmune LLC.

Explore the full profile